Aptabio Therapeutics Inc.
Develops drugs for intractable diseases by regulating oxidative stress and CAFs.
293780 | KO
Overview
Corporate Details
- ISIN(s):
- KR7293780003
- LEI:
- Country:
- South Korea
- Address:
- 경기도 용인시 기흥구 흥덕1로 13 타워동 에이504호(영덕동, 흥덕아이티밸리), 용인시
- Website:
- https://aptabio.com/
- Sector:
- Manufacturing
Description
Aptabio Therapeutics Inc. is a biopharmaceutical company dedicated to developing first-in-class drugs for intractable diseases with high unmet medical needs. The company's research is driven by proprietary platform technologies. One core platform focuses on regulating oxidative stress through selective NOX (NADPH oxidase) inhibitors, targeting the root causes of inflammation and fibrosis to treat diabetic complications, vascular diseases, and neurodegenerative disorders. A second platform centers on the regulation of cancer-associated fibroblasts (CAF) to overcome resistance and enhance the efficacy of immuno-oncology therapies for difficult-to-treat cancers. By leveraging these distinct approaches, Aptabio aims to discover and advance novel therapeutic candidates for challenging medical conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-08-03 00:00 |
투자판단관련주요경영사항(당뇨병성 신증 치료제 APX-115의 유럽 임상 2상 시험 계획(IND) 승인)
|
Korean | 11.5 KB | ||
| 2020-06-19 00:00 |
기타경영사항(특허권취득)(자율공시)(3-페닐-4-프로필-1-(피리딘-2-일)-1H-피라졸-5-올 염산염의 신규 결정형 고체화합물)
|
Korean | 5.6 KB | ||
| 2020-06-12 00:00 |
투자판단관련주요경영사항(당뇨병성 신증 치료제 APX-115의 유럽 임상 2상 시험 계획(IND) 승인)
|
Korean | 11.5 KB | ||
| 2020-06-10 00:00 |
투자판단관련주요경영사항(당뇨병성 신증 치료제 APX-115의 유럽 임상 2상 시험 계획(IND) 승인)
|
Korean | 11.5 KB | ||
| 2020-06-04 00:00 |
기타경영사항(특허권취득)(자율공시)(간질환 치료제)
|
Korean | 6.0 KB | ||
| 2020-05-20 00:00 |
투자판단관련주요경영사항(당뇨병성 신증 치료제 APX-115의 유럽 임상 2상 시험 계획(IND) 승인)
|
Korean | 11.5 KB | ||
| 2020-05-15 00:00 |
분기보고서 (2020.03)
|
Korean | 710.9 KB | ||
| 2020-04-28 00:00 |
기타경영사항(특허권취득)(자율공시)(신증 진단용 마커로서의 SH3YL1의 용도)
|
Korean | 5.9 KB | ||
| 2020-04-10 00:00 |
주식등의대량보유상황보고서(약식)
|
Korean | 58.4 KB | ||
| 2020-04-02 00:00 |
기타경영사항(특허권취득)(자율공시)
|
Korean | 5.8 KB | ||
| 2020-03-30 00:00 |
주식매수선택권행사
|
Korean | 19.5 KB | ||
| 2020-03-27 00:00 |
정기주주총회결과
|
Korean | 23.2 KB | ||
| 2020-03-27 00:00 |
사업보고서 (2019.12)
|
Korean | 362.0 KB | ||
| 2020-03-19 00:00 |
감사보고서제출
|
Korean | 20.6 KB | ||
| 2020-03-17 00:00 |
[기재정정]주주총회소집공고
|
Korean | 433.0 KB |
Automate Your Workflow. Get a real-time feed of all Aptabio Therapeutics Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Aptabio Therapeutics Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Aptabio Therapeutics Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
